Product Data Sheet

Maleimido-tri(ethylene glycol)-propionic acid

Cat. No.:	HY-130426		
CAS No.:	518044-40-1	L	
Molecular Formula:	C ₁₃ H ₁₉ NO ₇		
Molecular Weight:	301.29		
Target:	ADC Linker; PROTAC Linkers		
Pathway:	Antibody-drug Conjugate/ADC Related; PROTAC		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (3	DMSO : 100 mg/mL (331.91 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	3.3191 mL	16.5953 mL	33.1906 mL		
		5 mM	0.6638 mL	3.3191 mL	6.6381 mL		
		10 mM	0.3319 mL	1.6595 mL	3.3191 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.30 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (8.30 mM); Suspended solution; Need ultrasonic						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.30 mM); Clear solution						

BIOLOGICAL ACTIV	
Diological	
Description	Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Maleimido-tri(ethylene glycol)-propionic acid is used for the preparation of neolymphostin-based ADC precursors site-specific cysteine mutant trastuzumab-A114C conjugation ^[1] . Maleimido-tri(ethylene glycol)-propionic acid also can be used as a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
IC ₅₀ & Target	Cleavable PEGs





In Vitro	 Mal-PEG3-C2-acid can be used to synthesis linker-payload 16 (compound 15) and 20 (compound 18). linker-payload 16 amd 20 is conjugated to DAR1.9 and DAR1.7^[1]. ADC 23 and 24 are Neolymphostin ADCs that composes of DAG 1.9 and DAG1.7 linked to PIKK inhibitors with linker-payload 16 and 20, respectively^[1]. ADC24 demonstrates cytotoxic activity against BT474 and N87 cell lines with IC₅₀ of 195 and 202 nM, respectively^[1]. ADC23 demonstrates cytotoxic activity against BT474 and N87 cell lines with IC₅₀ of 286 and 274 nM, respectively^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
----------	--

REFERENCES

[1]. Zhou D, et al. Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity. Bioorg Med Chem Lett. 2019 Apr 1;29(7):943-947.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA